Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 5/20 | 0.64 |
| ▸ | RARB | P10826 | 5/20 | 0.64 |
| ▸ | RXRA | P19793 | 4/20 | 0.64 |
| ▸ | RXRB | P28702 | 4/20 | 0.64 |
| ▸ | RXRG | P48443 | 4/20 | 0.64 |
| ▸ | CNR1 | P21554 | 8/20 | 0.54 |
| ▸ | PLEC | Q15149 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5064844 | 0.86 | PLEC (0.67) | RARARARBRXRARXRBRXRG | |
| SCHEMBL1366387 | 0.85 | HDAC1 (0.63) | RARARARBRXRARXRBRXRG | |
| SCHEMBL5443827 | 0.85 | IDO1 (0.50) | RARARARBRXRARXRBRXRG | |
| SCHEMBL7954347 | 0.81 | CNR1 (0.55) | RARARARBRXRARXRBRXRG | |
| SCHEMBL1132787 | 0.79 | USP2 (0.47) | RARARARBRXRARXRBRXRG | |
| SCHEMBL8022153 | 0.79 | CNR1 (0.46) | RARARARBRXRARXRBRXRG | |
| SCHEMBL13343063 | 0.79 | RXRA (1.00) | RARARARBRXRARXRBRXRG | |
| SCHEMBL29354228 | 0.79 | RXRA (1.00) | RARARARBRXRARXRBRXRG | |
| SCHEMBL1364761 | 0.75 | HDAC3 (0.73) | RARARARBRXRARXRBRXRG | |
| SCHEMBL1367824 | 0.74 | MAPT (0.57) | RARARARBRXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| EP-2966078-A2 | Inhibitors of histone deacetylase | MethylGene Inc. (CA) | 2016-01-13 | — | — | EP | disclosed |
| US-9193749-B2 | Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors | FORUM PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| EP-2343286-B1 | Dibenzo[b,f][1,4]oxazepine derivatives as inhibitors of histone deacetylase | METHYLGENE INC (CA) | 2014-12-31 | — | — | EP | disclosed |
| US-20140011988-A1 | Dibenzo[B,F][1,4]Oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2014-01-09 | — | — | US | disclosed |
| US-8399452-B2 | Anticancer agents; antiproliferative agenst; antiprotozoa agents | METHYLGENE INC. (CA) | 2013-03-19 | — | — | US | disclosed |
| EP-2489657-A2 | Inhibitors of histone deacetylase | MethylGene Inc. (CA) | 2012-08-22 | — | — | EP | disclosed |
| US-20110288070-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-11-24 | — | — | US | disclosed |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-08-11 | — | — | US | disclosed |
| EP-2343286-A1 | Dibenzo[b,f][1,4]oxazepine derivatives as inhibitors of histone deacetylase | Methylgene, Inc. (CA) | 2011-07-13 | — | — | EP | disclosed |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288070-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC2 | RARA 2842/4885RARB 1681/4885RXRA 1722/4885 |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC11 | RARA 1174/4885RARB 676/4885RXRA 790/4885 |
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC2 | RARA 2842/4885RARB 1681/4885RXRA 1722/4885 |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | HDAC5, KAT2A, HDAC1 | RARA 2473/4885RARB 1175/4885RXRA 1507/4885 |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | HDAC1, HDAC2, HDAC4 | RARA 2759/4885RARB 1096/4885RXRA 1444/4885 |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC11 | RARA 1174/4885RARB 676/4885RXRA 790/4885 |
| US-20140011988-A1 | Dibenzo[B,F][1,4]Oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | HDAC1, HDAC2, HDAC4 | RARA 2759/4885RARB 1096/4885RXRA 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.